In vitro immunoregulatory effects of antidepressants in healthy volunteers

Polish Journal of Pharmacology

Volumn 55, Issue 3, 2003, Pages 353-362

  Szuster Ciesielska, Agnieska ^a   Tustanowska Stachura, Anna ^a   Słotwińska, Maria ^a   Marmurowska Michałowska, Halina ^b   Kandefer Szerszeń, Martyna ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antidepressants; Cytokines; Imipramine; Lithium; Mianserin; Peripheral blood leukocytes; Reactive oxygen species

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CYTOKINE; GAMMA INTERFERON; IMIPRAMINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; LITHIUM CARBONATE; LYMPHOTOXIN; MIANSERIN; NEUROLEPTIC AGENT; PHYTOHEMAGGLUTININ; REACTIVE OXYGEN METABOLITE; ROLIPRAM; SEROTONIN UPTAKE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TRICYCLIC ANTIDEPRESSANT AGENT;

APOPTOSIS; ARTICLE; CELL KILLING; CELL STIMULATION; CELL SUBPOPULATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; IN VITRO STUDY; INCUBATION TIME; INFLAMMATION; LEUKOCYTE FUNCTION; MAJOR DEPRESSION; MALE; MONONUCLEAR CELL; NEUTROPHIL; POLYCLONAL ACTIVATION; RESPIRATORY BURST; TH1 CELL; TH2 CELL; VOLUNTEER;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIDEPRESSIVE AGENTS; APOPTOSIS; CYTOKININS; FEMALE; HUMANS; IMIPRAMINE; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LITHIUM; MALE; MIANSERIN; NEUTROPHILS; PHYTOHEMAGGLUTININS; REACTIVE OXYGEN SPECIES;

EID: 0043032855     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Arena A., Capozza A.B., Orlando M.E., Curro F., Losi E., Chillemi S., Mesiti M., Merendino R.A.: In vitro effects of lithium chloride on TNF alpha and IL-6 production by monocytes from breast cancer patients. J. Chemother., 1997, 9, 219-226.
2. Bilici M., Efe H., Koroglu M.A., Uydu H.A., Bekaroglu M., Deger O.: Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J. Affect. Disorders, 2001, 64, 43-51.
3. Bluthe R.M., Castanon N., Pousset F., Bristow A., Ball C., Lestage J., Michaud B., Kelley K.W., Danzer R.: Central injection of IL-10 antagonizes the behavioural effects of lipopolysaccharide in rats. Psychoneuroendocrinology, 1999, 24, 301-311.
4. Bohus M., Forstner U., Kiefer C., Gebicke-Harter P.J., Timmer J., Spraul G., Wark H.J., Hecht H., Berger M., van Calker D.: Increased sensitivity of the inositolphospholipid system in neutrophils from patients with acute major depressive episodes. Psychiat. Res., 1996, 65, 45-51.
5. Caruso C., Candore G., Cigna D., Colucci A.T., Modica M.A.: Biological significance of soluble IL-2 receptor. Mediat. Inflamm., 1993, 2, 3-21.
6. Cavaillon J.M.: Les Cytokines. Ed. Cavaillon J.M., Masson, Paris, 1996.
7. 2+ response in neutrophils from patients under chronic lithium therapy. Eur. Arch. Psychiat. Clin. Neurosci., 1994, 243, 240-243.
8. Frank M.G., Hendricks S.E., Bessette D., Johnson D.R., Wieseler F.J.L., Burke W.J.: Levels of monocyte reactive oxygen species are associated with reduced natural killer cell activity in major depressive disorder. Neuropsychobiology, 2001, 44, 1-6.
9. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., Berger M.: Interleukin 6 (IL-6) plasma levels in depression and schizophrenia: comparison between acute state and after remission. Eur. Arch. Psychiat. Clin. Neurosci., 1997, 247, 228-233.
10. Fülöp T., Varga Z., Jacob M.P., Robert L.: Effect of lithium on superoxide production and intracellular free calcium mobilization in elastin peptide (kappa elastin) and FMLP stimulated human PMNS, effect of age. Life Sci., 1997, 60, 325-332.
11. Hadjimitova V., Traykov T., Goliysky P., Ribarov S.: Effect of some psychotropic drugs on the activated macrophage-induced luminol-dependent chemiluminescence. Pharmacol. Toxicol., 1999, 84, 170-173.
12. Johnson R.W., Propes M.J., Shavit Y.: Corticosterone modulates behavioural and metabolic effects of lipopolysaccharide. Amer. J. Physiol., 1996, 270, R 192-198.
13. Kamińska T., Marmurowska-Michałowska H., Duba-Ślemp H., Wysocka A., Kandefer-Szerszeń M.: Cytokine production in major depression. I. The role of proinflammatory cytokines and Th1/Th2 dysfunction. Cent. European J. Immunol., 2002, 27, in press.
14. Krieglstein K., Strelau J., Schober A., Sullivan A., Unsicker K.: TGF-beta and the regulation of neuron survival and death. J. Physiol.-Paris, 2002, 96, 25-30.
15. Kubera M., Holan V., Mathison R., Maes M.: The effect of repeated amitriptyline and desimipramine administration on cytokine release in C57BL/6 mice. Psychoneuroendocrinology, 2000, 25, 785-797.
16. Kubera M., Lin A.H., Kenis G., Bosman E., Van Bockstaele D., Maes M.: Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma-interleukin-10 production ration. J. Clin. Psychopharmacol., 2001, 21, 199-206.
17. Kubera M., Symbirtsev A., Basta-Kaim A., Borycz J., Roman A., Papp M., Claesson M.: Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol. J. Pharmacol., 1996, 48, 503-506.
18. Kucharz E.J., Sierakowski S.J., Goodwin J.S.: Lithium in vitro enhances interleukin-2 production by T cells from patients with systemic lupus erythematosus. Immunopharmacol. Immunotoxicol., 1993, 5, 515-523.
19. Lentsch A.B., Shanley T.P., Sarma V., Ward P.A.: In vivo suppression of NF-kB and preservation of IkBα by interleukin-10 and interleukin-13. J. Clin. Invest., 1997, 100, 2443-2448.
20. Maes M., Bosmans E., Meltzer H.Y., Charpe S., Suy E.: Interleukin-1β: a putative mediator of HPA-axis hyperactivity in major depression? Amer. J. Psychiat., 1993, 150, 1189-1193.
21. Maes M., De Vos N., Pioli R., Demendts P., Wauters A., Neels H., Christophe A.: Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J. Affect. Disorders, 2000, 58, 241-246.
22. Maes M., Meltzer H.Y., Bosmans E., Bergmans R., Vandoolaeghe E., Ranjan R., Desnyder R.: Increased plasma concentrations of interleakin-6, soluble interleukin-6, soluble interleukin-2 and transferring receptor in major depression. J. Affect. Disorders, 1995, 34, 301-309.
23. Maes M., Scharpe S., Meltzer H.Y., Okayli G., Bosmans E., D'Hondt P., Vanden Bossche B., Cosyns P.: Increased neopterin and interferon-γ secretion and lower availability of L-tryptophan in major depression: further evidence for activation of cell-mediated immunity. Psychiat. Res., 1994, 54, 143-160.
24. Maes M. Smith R.S.: Fatty acids, cytokines, and major depression. Biol. Psychiat., 1998, 34, 313-314.
25. Maes M., Song C., Lin A.H., Pioli R., Kenis G., Kubera M., Bosman E.: In vitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacology, 1999, 143, 401-407.
26. Maes M., Vandoolaeghe E., Van Hunsel F., Bril T., Demends P., Wauters A., Neels H.: Immune disturbances in treatment-resistant depression: modulation by antidepressive treatment. Hum. Psychopharmacol., 1997, 12, 153-162.
27. Mayo L.A., Curnutte J.T.: Kinetic microplate assay for superoxide production by neutrophils and other phagocytic cells. Meth. Enzymol., 1990, 186, 571-575.
28. Melzacka M., Sas-Korczyńska A., Syrek M.: The effect of imipramine on lipid peroxidation in the rat cerebral cortex. Pol. J. Pharmacol., 1995, 47, 25-30.
29. Nibuya M., Morinobu S., Duman R.S.: Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci., 1995, 15, 7539-7547.
30. Nibuya M., Nestler E.J., Duman R.S.: Chronic antidepressant administration increases the expression of cAMP response binding protein (CREB) in rat hippocampus. J. Neurosci., 1996, 16, 2365-2372.
31. O'Shea J.J., Visconti R.: Type 1 IFNs and regulation of Th1 responses: enigmas both resolved and emerging. Nat. Immunol., 2000, 1, 17-19.
32. Park A.Y., Scott P.: IL-12: keeping cell-mediated immunity alive. Scand. J. Immunol., 2001, 53, 529-532.
33. Pick E.: Microassays for superoxide and hydrogen peroxide production and nitroblue tetrazolium reduction using and enzyme immunoassay microplate reader. Meth. Enzymol., 1986, 132, 414-419.
34. Rapaport M.H., Guylai L., Whybrow P.: Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J. Psychiat. Res., 1999, 33, 335-340.
35. Rapaport M.H., Manji H.K.: The effects of lithium on ex vivo cytokine production. Biol. Psychiat., 2001, 50, 217-224.
36. Rapaport M.H., Schmidt M.E., Risinger R., Manji H.: The effects of prolonged lithium exposure on the immune system of normal control subjects: serial serum soluble interleukin-2 receptor and antithyroid antibody measurements. Biol. Psychiat., 1994, 15, 761-766.
37. Seidel A., Arolt V., Hunstiger M., Rink L., Behnish A., Kirchner H.: Increased CD56+ natural killer cells and related cytokines in major depression. Clin. Immunol. Immunopathol., 1996, 78, 83-85.
38. Shen Y., Connor T.J., Nolan Y., Kelly J.P., Leonard B.E.: Differential effect of chronic antidepressant treatment on lypopolysaccharide-induced depressive-like behavioural symptoms in the rat. Life Sci., 1999, 65, 1773-1786.
39. Słuzewska A., Rybakowski J.K., Laciak M., Mackiewicz A., Sobieska M., Wiktorowicz K.: Interleukin 6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. NY Acad. Sci., 1995, 762, 474-476.
40. Słuzewska A., Rybakowski J. Sobieska M., Bosmans E., Pollet H. Wiktorowicz K.: Increased levels of alpha-1-acid glycoprotein and IL-6 in refractory depression. Depression, 1995, 3, 170-175.
41. Słuzewska A., Wiktorowicz K., Mackiewicz S.H., Rybakowski J.K.: The effect of short term treatment with lithium and carbamazepine on some immunological indices in depressed patients. Lithium, 1994, 5, 41-46.
42. Smejkal-Jagar L., Boranic M.: Serotonin, serotonergic agents and their antagonists suppress humoral immune reactions in vitro. Res. Exp. Med., 1994, 194, 297-304.
43. Smith R.S.: The macrophage theory of depression. Med. Hypotheses, 1991, 35, 298-306.
44. Sommer N., Loschman P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A. et al.: The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med., 1995, 1, 211-214.
45. Song C., Dinan T., Leonard B.E.: Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J. Affect. Disorders, 1994, 30, 283-288.
46. Wakefield L.M., Roberts A.B.: TGF-beta signalling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev., 2002, 12, 22-29.
47. Weiss G., Murr C., Zoller H., Haun M., Wider B., Ludescher C., Fuchs D.: Modulation of neopterin formation and tryptophan degradation by Th1 and Th2 derived cytokines in human monocytic cells. Clin. Exp. Immunol., 1999, 116, 435-440.
48. Xia Z., DePierre J.W., Nassberger L.: Tricyclic antidepressants inhibit IL-6, IL-1β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T cells. Immunopharmacology, 1996, 34, 27-37.
49. Yirmiya R.: Endotoxin produces a depressive-like episode in rats. Brain Res., 1996, 711, 163-174.
50. Yirmiya R.: Behavioral and psychological effects of immune activation: implications for depression due to a general medical condition. Curr. Opinion Psychiat., 1997, 10, 470-476.
51. Young M.R., Matthews J.P.: Serotonin regulation of T cell subpopulations and of macrophage accessory function. Immunology, 1995, 84, 148-152.